RxDoctor Payments Data

Rudolph Newman, MD

Ophthalmology · Columbia, SCNPI 1801858469

Payments from drug & device makers

$718in general payments, 2019–2025

Across 32 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$325
  • AbbVie$85
  • Amgen$73
  • Sun Pharmaceutical Industries Inc.$66
  • Carl Zeiss Meditec USA, Inc.$31
  • Novartis$27
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$718 in reported general payments places this provider in the 25th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$356,931
Medicare patients
1,627
Services billed
6,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost168$68,832
Cyclosporine82$44,332
RestasisCyclosporine28$33,413
Bromfenac Sodium50$10,016
VyzultaLatanoprostene Bunod14$7,472
ProlensaBromfenac Sodium21$7,248
Prednisolone Acetate136$7,187
IlevroNepafenac18$6,719
CombiganBrimonidine Tartrate/Timolol14$6,506
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$5,178
Brimonidine Tartrate64$5,136
Latanoprost399$3,996
Timolol Maleate232$3,586
Travoprost30$3,051
MoxifloxacinMoxifloxacin Hcl139$2,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$85$108,751210 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$19$8,28832 claims
Bausch & Lomb Americas Inc.Vyzulta$14$7,47214 claims
NovartisIlevro$27$6,71918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →